Biosensia is an in vitro diagnostics company that has developed a novel point of care platform, RapiPlex, available for licensing.

RapiPlex is a point of care in vitro diagnostic non-lateral flow platform unlike any other on the market. Using proven and tested technology, it can perform up to twelve separate analyses simultaneously on a single sample and provide assay results in less than 15 minutes.

The RapiPlex platform integrates an optical reader to provide a numerical read-out, which does not require user interpretation. The RapiPlex platform has application in a wide variety of point of care immunodiagnostic assays.



Company and Product Information Downloads:
Biosensia Corporate Presentation

Latest News RSS Feed